Company: MIRA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010301
Chunk: 32

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 2
Chunk 32
---
rez Aminov

    31.1*
     
    Certification of Chief Executive Officer Pursuant to Sarbanes-Oxley Section 302

    31.2*
     
    Certification of Interim Chief Financial Officer Pursuant to Sarbanes-Oxley Section 302

    32.1**
     
    Certification Pursuant To 18 U.S.C. Section 1350 (*)

    32.2**
     
    Certification Pursuant To 18 U.S.C. Section 1350 (*)

    101.ins*
     
    Inline
    XBRL Instance Document

    101.sch*
     
    Inline
    XBRL Taxonomy Extension Schema Document

    101.cal*
     
    Inline
    XBRL Taxonomy Calculation Linkbase Document

    101.def*
     
    Inline
    XBRL Taxonomy Definition Linkbase Document

    101.lab*
     
    Inline
    XBRL Taxonomy Label Linkbase Document

    101.pre*
     
    Inline
    XBRL Taxonomy Presentation Linkbase Document

    104*
     
    The
    cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL.

    *
     
    Filed
    herewith.

    **
     
    Furnished
    herewith.

 20 

SIGNATURES

Pursuant
to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

    MIRA
    PHARMACEUTICALS, INC.

    Date:
    May 14, 2025
    By:
    /s/
    Erez Aminov                

    Erez
    Aminov

    Chief
    Executive Officer

    (Principal
    Executive Officer)

    Date:
    May 14, 2025
    By:
    /s/
    Michelle Yanez

    Michelle
    Yanez

    Chief
    Financial Officer, Treasurer and Secretary

    (Principal
    Financial Officer)

 21